BrightView Holdings, Inc., through its subsidiaries, provides commercial landscaping services in the United States. It operates in two segments, Maintenance Services and Development Services. The Maintenance Services segment delivers a suite of recurring commercial landscaping services, including mowing, gardening, mulching and snow removal, water management, irrigation maintenance, tree care, golf course maintenance, and specialty turf maintenance. Its customers' properties include corporate and commercial properties, homeowners associations, public parks, hotels and resorts, airport authorities, municipalities, hospitals and other healthcare facilities, educational institutions, restaurants and retail, and golf courses. This segment's customer base includes approximately 11,700 office parks and corporate campuses 10,000 residential communities, and 700 educational institutions. The Development Services segment offers landscape architecture and development services for new facilities and redesign projects. Its services include project design and management services, landscape architecture and installation, irrigation installation, tree moving and installation, pool and water features, sports field, and other services. BrightView Holdings, Inc. also operates as official field consultant to Major League Baseball. The company was formerly known as BrightView Acquisition Holdings, Inc. BrightView Holdings, Inc. was founded in 1939 and is headquartered in Blue Bell, Pennsylvania.

BrightView Holdings Inc.

Bioventix ( ($GB:BVXP) ) has issued an announcement. Bioventix has disclosed that chief executive Peter Harrison and his wife Abigail have each pur...

Bioventix CEO Increases Stake After Share Purchases with Spouse

There’s a lot to be optimistic about in the Industrial Goods sector as 2 analysts just weighed in on Kirby (KEX) and BrightView Holdings (BV) with ...

Analysts’ Top Industrial Goods Picks: Kirby (KEX), BrightView Holdings (BV)

Banco Bilbao ( ($BBVA) ) just unveiled an update. BBVA has provided an update on the second tranche of its ongoing share buyback program, carried o...

BBVA Nears Halfway Mark in Second Tranche of Share Buyback

Abbvie ($ABBV) announced an update on their ongoing clinical study. The AbbVie (ABBV) study “Observational Prospective Study to Evaluate Effectiven...

AbbVie’s Real‑World Parkinson’s Study in Belgium: What Investors Should Watch

The latest announcement is out from Vistry Group ( ($GB:VTY) ). Vistry Group PLC has continued to execute its share buyback programme, repurchasing...

Vistry Cancels Further Shares as Buyback Tightens Free Float

Scotiabank analyst Louise Chen maintained a Buy rating on AbbVie today and set a price target of $280.00. According to TipRanks, Chen is a 4-star a...

AbbVie (ABBV) Gets a Buy from Scotiabank

Analysts fell to the sidelines weighing in on AbbVie (ABBV), Takeda Pharmaceutical Co (TKPHF) and Hims & Hers Health (HIMS) with neutral ratings, i...

Analysts’ Top Healthcare Picks: AbbVie (ABBV), Takeda Pharmaceutical Co (TKPHF)

In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on DBV Technologies SA – American, with a price target of $46....

DBV Technologies SA – American (DBVT) Receives a Rating Update from a Top Analyst

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie (ABBV) has completed a real world study called “Prospective Observationa...

AbbVie’s Real-World Migraine Study Nears Data Release: What Investors Should Watch

In a report released on April 1, Anthony Codling from RBC Capital maintained a Sell rating on Vistry Group, with a price target of p180.00. The com...

RBC Capital Keeps Their Sell Rating on Vistry Group (VTY)

In a report released on April 1, Francois Digard from Kepler Capital maintained a Buy rating on Bureau Veritas, with a price target of €35.00. The ...

Kepler Capital  Keeps Their Buy Rating on Bureau Veritas (0MH1)

Baronsmead Venture ( ($GB:BVT) ) has provided an announcement. Baronsmead Venture Trust plc reported a share transaction involving non-executive di...

Baronsmead Venture Trust Discloses Director Share Purchase via Dividend Reinvestment Plan

An announcement from Itau Unibanco ( ($ITUB) ) is now available. Itaú Unibanco Holding S.A. disclosed on April 1, 2026, that it and its controlled ...

Itaú Unibanco Details BRL 441 Million 2026 Related-Party Insurance Agreement With Porto Seguro

Baronsmead Venture ( ($GB:BVT) ) has provided an update. Baronsmead Venture Trust has allotted 19,264,047 new ordinary shares under its ongoing sub...

Baronsmead Venture Trust Expands Share Allotment and Extends VCT Offer Into 2026/27

Itau Unibanco ( ($ITUB) ) has shared an announcement. Itaú Unibanco has published its Risk and Capital Management – Pillar 3 report for the fourth ...

Itaú Unibanco Files Q4 2025 Pillar 3 Risk and Capital Report With Strong Capital Ratios

An announcement from Bravura Solutions Limited ( ($AU:BVS) ) is now available. Bravura Solutions Limited has notified the market of the issue or co...

Bravura Solutions Flags Conversion of Unquoted Equity Securities

Breville Group ( ($AU:BRG) ) has shared an announcement. Breville Group Limited has notified the market of the cessation of 8,504 performance right...

Breville Confirms Lapse of 8,504 Performance Rights

Bravura Solutions Limited ( ($AU:BVS) ) has provided an update. Bravura Solutions Limited has announced a change in its corporate governance team, ...

Bravura Solutions Reshapes Governance Team With New Joint Company Secretaries

BioVaxys Technology ( ($TSE:BIOV) ) just unveiled an announcement. BioVaxys Technology Corp., a clinical-stage biopharmaceutical company focused on...

BioVaxys Updates on Filing Delays as Executives Face Trading Restrictions

An update from Banco Bilbao Vizcaya Argentaria ( ($ES:BBVA) ) is now available. BBVA has executed a partial share capital reduction approved at its...

BBVA Cancels 75 Million Treasury Shares in Partial Capital Reduction

Baronsmead Venture ( ($GB:BVT) ) has issued an announcement. Baronsmead Venture Trust plc has repurchased 455,879 of its own ordinary shares at 42....

Baronsmead Venture Trust Tightens Free Float With Treasury Share Buyback

Vistry Group ( ($GB:VTY) ) just unveiled an announcement. Vistry Group PLC has updated investors on its share capital, confirming it now has 319,17...

Vistry Updates Share Capital and Voting Rights After Buyback

Itau Unibanco ( ($ITUB) ) has shared an update. On March 27, 2026, Itaú Unibanco released its manual for the Annual and Extraordinary General Stock...

Itaú Unibanco Sets April 28, 2026 Online Shareholder Meetings to Vote on 2025 Results and Itaucard Merger

Itau Unibanco ( ($ITUB) ) just unveiled an announcement. Itaú Unibanco has called an Annual General Stockholders’ Meeting and an Extraordinary Gene...

Itaú Unibanco Sets April 28, 2026 Online Meetings to Approve 2025 Results and Itaucard Merger

Itau Unibanco ( ($ITUB) ) has provided an update. On February 23, 2026, Itaú Unibanco’s Fiscal Council met in São Paulo to evaluate a proposed merg...

Itaú Unibanco Fiscal Council Backs Merger of Itaucard Into Holding Company

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on DBV Technologies SA – American on March 27 and set a price target of $48.00. The com...

DBV Technologies SA – American (DBVT) Receives a Buy from LifeSci Capital

The latest update is out from Vistry Group ( ($GB:VTY) ). Vistry Group PLC has adjusted its disclosure practices for share repurchases to align wit...

Vistry shifts to weekly buyback disclosures as it cancels 28,000 shares

Bioventix ( ($GB:BVXP) ) just unveiled an announcement. Bioventix reported a modest dip in interim revenue to £6.16m and profit before tax to £4.85...

Bioventix Leans on Neuro Antibodies as Interim Profits Hold Steady

Kepler Capital analyst Justine Telliez maintained a Buy rating on DBV Technologies on March 27 and set a price target of €5.50. The company’s share...

Kepler Capital  Sticks to Its Buy Rating for DBV Technologies (0QAJ)

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Abivax SA Sponsored ADR today and set a price target of $170.00. According to TipRan...

Abivax SA Sponsored ADR (ABVX) Receives a Rating Update from a Top Analyst

Kepler Capital analyst Thomas Renaud maintained a Buy rating on Claranova SA on March 26 and set a price target of €2.60. The company’s shares clos...

Kepler Capital  Sticks to Its Buy Rating for Claranova SA (0N6K)

The latest update is out from ABVC BioPharma ( ($ABVC) ). On March 26, 2026, ABVC BioPharma held its 2026 annual shareholder meeting, where investo...

ABVC BioPharma Shareholders Back Board, Equity Plan Changes

Vistry Group ( ($GB:VTY) ) has provided an update. Vistry Group has granted a series of conditional share awards to its top executives under the co...

Vistry grants nil-cost deferred bonus share awards to senior executives

Vistry Group ( ($GB:VTY) ) has shared an announcement. Vistry Group has disclosed that a series of awards granted on 27 March 2023 under its Long T...

Vistry Executives Lose 2023 Long-Term Share Awards as Targets Missed

Itau Unibanco ( ($ITUB) ) just unveiled an announcement. Itaú Unibanco Holding S.A. announced on March 26, 2026, that it issued Tier 2 subordinated...

Itaú Unibanco Issues R$3.3 Billion in Tier 2 Subordinated Financial Bills

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on DBV Technologies SA – American yesterday and set a price target of $48.00. The ...

DBV Technologies SA – American (DBVT) Gets a Buy from Cantor Fitzgerald

Tao Heung Holdings Limited ( ($HK:0573) ) just unveiled an announcement. Tao Heung Holdings reported a 4.4% decline in revenue to HK$2.32 billion f...

Tao Heung Widens 2025 Loss as Weak Demand and Fierce Competition Pressure Margins

An update from Above Food Ingredients ( ($ABVE) ) is now available. Above Food Ingredients Inc. on March 20, 2026 addressed recent market speculati...

Above Food Addresses Trading Speculation and Nasdaq Compliance as Audit Nears Completion

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Abivax SA Sponsored ADR (ABVX), Compass Therapeutics...

Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), Compass Therapeutics (CMPX) and Talphera (TLPH)

The latest announcement is out from Vistry Group ( ($GB:VTY) ). Vistry Group has reported the vesting of conditional share awards for several senio...

Vistry Executives Vest and Sell Shares to Cover Tax Liabilities

It’s been a tough few weeks for investors and stock pickers, but U.S. Chess champion Hikaru Nakamura is keeping his head well above water in his Ti...

U.S. Chess Champion Hikaru Stays Ahead of the S&P Thanks to Tech, Oil and Health Stocks

In a report released today, from Macquarie maintained a Buy rating on Breville Group , with a price target of A$37.10. In addition to Macquarie, Br...

Macquarie Remains a Buy on Breville Group  (BVILF)

The Schwab U.S. Dividend Equity ETF ($SCHD) has been one of the strongest performers of 2026, outgaining the S&P 500 ($SPX) by over 12% so far this...

SCHD ETF Slips Ahead of Portfolio Reshuffle — UNH, QCOM In; HAL, VLO Out

Kepler Capital analyst Francois Digard maintained a Buy rating on Bureau Veritas on March 20 and set a price target of €35.00. The company’s shares...

In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Abivax SA Sponsored ADR, with a price target of $170.00. Ac...

LifeSci Capital Sticks to Their Buy Rating for Abivax SA Sponsored ADR (ABVX)

AbbVie ( ($ABBV) ) has fallen by -7.40%. Read on to learn why. AbbVie shares fell 7.40% over the past week, even as Wall Street analysts largely st...

AbbVie Stock Slides as Insider Selling Spooks Investors

The latest announcement is out from Banco Bilbao Vizcaya Argentaria ( ($ES:BBVA) ). BBVA has announced a significant event concerning a new share b...

BBVA Announces Significant Share Buyback Program

Prestige Consumer Healthcare ( ($PBH) ) has provided an announcement. On March 19, 2026, Prestige Brands, Inc., a wholly owned unit of Prestige Con...

Prestige Consumer to Acquire Breathe Right Brand Portfolio

The latest update is out from Bellavista Resources Ltd ( ($AU:BVR) ). Bellavista Resources has called a general meeting of shareholders for 22 Apri...

Bellavista Calls April 2026 Meeting to Approve FireFly Deal and Capital Changes

Breville Group ( ($AU:BRG) ) has issued an update. Greencape Capital has notified the market that it has ceased to be a substantial shareholder in ...

Greencape Capital Exits Substantial Holding in Breville Group

Breville Group ( ($AU:BRG) ) just unveiled an update. Breville Group Limited has reported a change in the interests of director Timothy Baxter, ref...

Breville Director Timothy Baxter Increases Holding via Fee Sacrifice Rights Issue

The latest announcement is out from Breville Group ( ($AU:BRG) ). Breville Group Limited has disclosed a change in the interests of non-executive d...

Breville Director Sally Herman Increases Equity Stake via Fee Sacrifice Scheme

Breville Group ( ($AU:BRG) ) just unveiled an update. Breville Group Limited has notified the ASX of the issue of 4,605 unquoted NED Rights as part...

Breville Issues New Unquoted NED Rights Under Director Incentive Scheme

Flexwork Properties ( ($TSE:BVCI) ) has provided an announcement. Blockchain Venture Capital Inc. has signed a non-binding letter of intent with Wo...

Blockchain Venture Capital Plans Reverse Takeover to Acquire Gold-Backed Digital Asset Business

In a report released yesterday, Cecilia Romero from Barclays maintained a Buy rating on Banco Bilbao Vizcaya Argentaria, with a price target of €21...

Banco Bilbao Vizcaya Argentaria (BVA) Receives a Buy from Barclays

Cobra Venture ( ($TSE:CBV) ) has shared an announcement. Cobra Venture Corporation and Robinson Energy Limited have signed a definitive agreement f...

Cobra Venture to Cede Control in Reverse Takeover by Robinson Energy

BioVaxys Technology ( ($TSE:BIOV) ) has provided an update. BioVaxys Technology Corp. reported that it remains under a management cease trade order...

BioVaxys Extends Financial Filing Delay Under Management Cease Trade Order

An update from Bouvet ASA ( ($DE:BV4) ) is now available. Bouvet ASA has been executing a share buy-back programme of up to 1,000,000 shares to sup...

Bouvet Buys Back 770,000 Shares to Fund Employee Equity Scheme

Vistry Group ( ($GB:VTY) ) has shared an announcement. Vistry Group disclosed routine share purchases under its Share Incentive Plan by Chief Finan...

Vistry Executives Add Shares Through Ongoing Incentive Plan Purchases

Leerink Partners analyst Faisal Khurshid initiated coverage with a Buy rating on Abivax SA Sponsored ADR yesterday and set a price target of $160.0...

Abivax SA Sponsored ADR (ABVX) Initiated with a Buy at Leerink Partners

Breville Group received a Buy rating and a A$37.20 price target from Ord Minnett analyst James Casey today. According to TipRanks, Casey is a 2-sta...

Positive Report for Breville Group  (BVILF) from Ord Minnett

The latest update is out from Bravura Solutions Limited ( ($AU:BVS) ). Bravura Solutions has adjusted the terms of the sign-on equity package for i...

Bravura Resets CEO Sign-On Option Price to Reflect Market Levels

In a report released today, Sam Teeger from Citi maintained a Buy rating on Breville Group , with a price target of A$39.85. Teeger covers the Cons...

Citi Reaffirms Their Buy Rating on Breville Group  (BVILF)

Citi analyst Borja Ramirez Segura reiterated a Buy rating on Banco Bilbao Vizcaya Argentaria on March 13. The company’s shares closed last Friday a...

Banco Bilbao Vizcaya Argentaria (BVA) Gets a Buy from Citi

In a report released today, Etzer Darout from Barclays maintained a Buy rating on Abivax SA Sponsored ADR, with a price target of $142.00. Darout c...

Barclays Remains a Buy on Abivax SA Sponsored ADR (ABVX)

An update from BioVaxys Technology ( ($TSE:BIOV) ) is now available. BioVaxys Technology and Adiverna have entered a research collaboration to deve...

BioVaxys and Adiverna Team Up on AI-Driven mRNA Vaccines for Pets

Abbvie ($ABBV) announced an update on their ongoing clinical study. The phase 1 study, officially titled “A Phase 1 Study in Healthy Subjects to As...

AbbVie Advances Risankizumab Dosing Study, Signaling Ongoing Immunology Investment

Bavarian Nordic A/S ($BVNRY) announced an update on their ongoing clinical study. Bavarian Nordic A/S is preparing a late‑stage trial aimed at prev...

Bavarian Nordic’s Phase 3b Chikungunya Vaccine Trial Sets Up a New Catalyst for BVNRY Investors

Baronsmead Venture ( ($GB:BVT) ) just unveiled an announcement. Baronsmead Venture Trust plc has released its quarterly factsheet for the three mon...

Baronsmead Venture Trust Publishes December 2025 Quarterly Factsheet

AbbVie ($ABBV) stock trades at a deep discount for a pharma company growing this fast. The market still seems anchored to an old narrative: that Ab...

AbbVie Stock (ABBV) Trades at a Discount Despite Fast Growth — a Bullish Case

Deutsche Bank analyst Alfredo Alonso Estudillo maintained a Buy rating on Banco Bilbao Vizcaya Argentaria today and set a price target of €21.25. A...

Banco Bilbao Vizcaya Argentaria (BVA) Receives a Rating Update from a Top Analyst

The latest announcement is out from Bellavista Resources Ltd ( ($AU:BVR) ). Bellavista Resources has released its half-year report for the period e...

Bellavista Resources Files Administrative Half-Year Report for December 2025 Period

The latest update is out from Itau Unibanco ( ($ITUB) ). Itaú Unibanco Holding S.A. disclosed a related-party transaction involving services provid...

Itaú Unibanco Discloses R$50 Million-Plus Related-Party Tech Services with Innovation Institute

In a report released today, Louise Chen from Scotiabank maintained a Buy rating on AbbVie, with a price target of $280.00. Chen covers the Healthca...

Scotiabank Reaffirms Their Buy Rating on AbbVie (ABBV)

Flexwork Properties ( ($TSE:BVCI) ) has provided an update. Blockchain Venture Capital Inc. has reshaped its board and capital structure, appointin...

Current Quarter	$0.06	Next Quarter	$0.28
Current Year	$0.59	Next Year	$0.67
QoQ Growth	+366.7%	YoY Growth	+13.6%
3Y EPS CAGR	-2.4%	Target Price	$16.46
Consensus	Buy	Upside	+39.5%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BV	$11.80	+3.69%	459.14K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BV	$11.80	+3.7%	459.14K
3
4
5
6

BV

BV

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get BrightView Holdings Inc. Data in Excel

Get BrightView Holdings Inc. Data in Excel